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Introduction
Estrogens are essential for development of the repro-
ductive system in women, in whom they exert beneficial
effects in a large number of tissues, including breast,
bone, brain, and cardiovascular system. In contrast, the
proliferation and genetic instability induced by estrogens
in breast and uterus have been considered to increase
further the likelihood that normal cells will transform into a
malignant type. Over the past 30 years a large number of
case–control and cohort studies have been conducted
that examined circulating levels of estrogens and/or their
urinary excretion to detect any differences in estrogen
concentrations that may contribute to cancer. Based on
their findings it has been suggested that increased
estrogen exposure for lengthy periods of time may induce
breast cancer [1–3].
Several observations have also associated in situ
production of hydroxylated estrogen metabolites, namely
catecholestrogens, with the development of estrogen-
sensitive cancers. Oxidative reactions are also important
because 2- and 4-hydroxylated metabolites possess
distinctive biologic properties as compared with estradiol
(E2), the 4-hydroxylated metabolites being particularly
important to the carcinogenic effects of estrogen [4–6]. It
is also important to emphasize that these metabolic
reactions not only take place in the liver but also in
estrogen target tissues such as breast, ovary and uterus,
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Abstract
The breast tissue is the site of major metabolic conversions of estradiol (E2) mediated by specific
cytochromes P450 hydroxylations and methylation by catechol-O-methyltransferase. In addition to E2
itself, recent findings highlight the significance of 4-hydroxylated estrogen metabolites as chemical
mediators and their link to breast cancer development and progression, whereas, in opposition, 2-
methoxylated estrogens appear to be protective. Recent data also indicate that breast tissue
possesses enzymatic machinery to inactivate and eliminate E2 and its oxidized and methoxylated
metabolites through conjugation catalyzed by UDP-glucuronosyltransferases (UGTs), which involves
the covalent addition of glucuronic acid. In opposition to other metabolic pathways of estrogen, the
UGT-mediated process leads to the formation of glucuronides that are devoid of biologic activity and
are readily excreted from the tissue into the circulation. This review addresses the most recent
findings on the identification of UGT enzymes that are responsible for the glucuronidation of E2 and
its metabolites, and evidence regarding their potential role in breast cancer.
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and thus they play a critical role in the local homeostasis
of E2 and its metabolites.
In addition to the hydroxylation of estrogen, it has been
known for many years that estrogen can be conjugated in
breast tissue. Conjugative estrogen metabolism includes
sulfonation [7,8], glucuronidation [9,10] and O-
methylation [11], which are catalyzed by sulfotransferases,
UDP-glucuronosyltransferases (UGTs) and catechol-O-
methyltransferase (COMT), respectively. Sulfates and
glucuronides are the most abundant circulating estrogen
conjugates [12]. Several recent observations support a
role for UGT enzymes in relation to estrogen metabolism
and cancer risk in estrogen target tissues [13–19]. This
review addresses the most recent findings regarding the
identification of UGT enzymes responsible for the
glucuronidation of E2 and its metabolites, and their
potential role in breast cancer susceptibility.
Site of production and secretion of estrogens
in women during aging
In comparison with men, who exhibit relatively constant
blood levels of androgen after puberty, circulating levels of
sex steroid hormones in women vary tremendously
throughout life. During ovarian cycles the follicles and the
corpus luteum are important sources of E2 and estrone
(E1), the serum concentrations of which range from 50 to
300 pg/ml and from 30 to 250 pg/ml, respectively
[20–23]. E1 sulfate (E1S) is also found in the circulation
(concentration approximately 1 ng/ml), but it is probably
formed by estrogen sulfotransferase, which is present in
several tissues (Fig. 1). In adult women the term
‘circulating estrogen’ is generally used to refer to E2, E1,
and E1S; the latter two represent a form of estrogen
storage and are precursors of E2 [20,22]. In addition to
the direct secretion of estrogens by the ovaries into the
bloodstream, a second source of estrogen in adult women
is through adrenal steroids such as dehydro-
epiandrosterone, its sulfate, and androstenedione (referred
as C19 steroids); these are converted to estrogen by the
aromatase enzyme (CYP19), which is expressed in several
extra-ovarian tissues, particularly adipose tissue [22,24,25].
At menopause, however, production of estrogen by the
ovaries is abolished. Despite the marked decline in
adrenal C19 steroid production observed in humans after
Figure 1
Estrogen biosynthesis and metabolism in breast tissue. In breast tissue, estrogens come directly from ovaries or they are synthesized from
androgens secreted by the adrenals. (1) The first metabolic pathway of estrogen involves the transformation of estradiol (E2) to estrone (E1) by
17β-hydroxysteroid dehydrogenase (17β-HSD) and its subsequent conjugation to estrone sulfate (E1S) by estrogen sulfotransferase. (2) Both E2
and E1 can be oxidized by the action of different cytochrome P450 enzymes to generate 2- and 4-hydroxy-catecholestrogen (OHCE). (3) These
metabolites can be further methoxylated by catechol-O-methyltransferase (COMT). (4) UDP-glucuronosyltransferases (UGTs) are able to conjugate
parent estrogens E2 and E1, as well as their derivatives 2/4-OHCE and 2/4-methoxy-catecholestrogen (MeOCE). The resulting estrogen
glucuronides are devoid of biologic activities. AR, androgen receptor; 3β-HSD, 3β-hydroxysteroid dehydrogenase; CYP19, aromatase; ∆5-diol,
androstenediol; DHT, dihydrotestosterone; ER, estrogen receptor; MeO, methoxy; OH, hydroxy; testo, testosterone.248
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age 30 years, these steroid precursors become the only
source of estrogen as substrates of CYP19 (Fig. 1)
[25–27]. Thus, the profile in the circulation is markedly
modified in postmenopausal women as compared with
premenopausal women; serum concentrations of E2 are
relatively low (about 2–10 pg/ml), whereas E1 (about
10–30 pg/ml) and E1S (about 150 pg/ml) exceed E2
concentrations [28]. By contrast, the concentrations of E2
in estrogen sensitive tissues are not significantly
decreased, despite the low serum E2 levels in menopausal
women [29,30]. In addition, several observations indicate
that, in the absence of ovarian production of estrogen, the
low concentrations of E2 in the circulation are not
representative of E2 content in tissue [23,29–33]. Indeed,
only a small fraction of E2 would be released from the
various tissues because of further local conversion of E2
into E1 and E1S, in addition to a series of polar metabolites
(Fig. 1). Thus, despite marked changes in blood estrogen
levels, the tissue content of estrogens and polar
metabolites appears to remain relatively constant during
aging. That a significant proportion of breast cancers
occur in postmenopausal women, with relatively low
circulating levels of E2 and its precursors E1 and E1S,
further supports this concept.
It has been hypothesized that homeostasis of tissue
concentrations of E2 and active metabolites may be
influenced significantly by the balance between the activity
of local estrogen producing enzymes and those that involve
conjugation and the activity of inactivation enzymes. In the
following section we address the various metabolic
transformations of E2 that take place in the breast tissue
and that lead to production of estrogen metabolites that
are substrates of UGT-inactivating enzymes.
Estrogen biosynthesis and metabolism in
breast tissue
There are essentially four major pathways of E2 metabolism
in estrogen-sensitive tissues (Fig. 1). The first involves
transformation of E2 to E1 and its subsequent conjugation to
E1S by 17β-hydroxysteroid dehydrogenase and estrogen
sulfotransferase, respectively. This pathway is considered to
enhance further the half-life of E2 because these enzymes
and those responsible for the back transformation of E1S to
E1 to E2 are present in several tissues of the body, including
the breast [34]. In contrast, the other three pathways, which
are active within target cells, generate estrogen metabolites
with distinctive biologic properties as compared with E2,
with only one metabolic process leading to complete
inactivation of estrogen (i.e. glucuronidation catalyzed by
UGT enzymes; Fig. 1).
The second pathway employs several cytochrome P450
(CYP) enzymes that use E2 and E1 as substrates for
extensive oxidative metabolism at various positions in the
estrogen molecule [35]. Recently, the specificity of 15
human CYPs to estrogen was thoroughly characterized by
Lee and coworkers [36], and they concluded that the
major oxidative products formed from E2 by CYPs are the
2-hydroxy-catecholestrogens (OHCEs) and 4-OHCEs
(Fig. 1). As indicated above, these catecholestrogens
possess distinct biologic properties as compared with E2.
For instance, several groups have postulated that the
depurinating adducts formed from 4-OHCEs may
generate mutations that initiate cancer, whereas 2-OHCE
metabolites may protect against cancer [4,6,35,37–40].
The formation of 2-OHCEs and 4-OHCEs in breast tissue
was recently studied by Rogan and coworkers [41]. Those
investigators quantified the total pool of conjugated and
nonconjugated E1, E2, their hydroxylated metabolites at
positions 2 and 4, and methylated derivatives of
catecholestrogens in breast tissue samples, after treat-
ment of tissue homogenates with glucuronidase/sulfatase
to release the corresponding unconjugated steroids. In
tissues obtained from healthy women, they found that
levels of the 2- and 4-hydroxy and/or methoxy metabolites
were within the same ranges as the parent estrogens E1
and E2 (about 1–2 ng/g tissue). In tumor tissues a
significant increase in 4-OHCE concentrations was noted,
which is in agreement with several previous reports that
indicated changes in estrogen metabolism in cancer
tissue that favour the 4-hydroxy pathway and formation of
the genotoxic catecholestrogen quinones [4,42]. As a
subsequent step to production of 2-OHCEs and 4-
OHCEs in mammary tissue, COMT adds a methyl group
to 2-OHCEs and, to a lesser degree, 4-OHCEs (Fig. 1)
[35,43,44].  O-methylation of 2-OHCE into 2-methoxy-
catecholestrogen results in the formation of a protective
metabolite with very potent inhibitory action on cell
proliferation, tubulin activity, and angiogenesis [45–47].
Overall, these data are in agreement with the concept that
E1 and E2 are converted by CYP and COMT in estrogen
sensitive tissues before their release into the circulation;
this would account for the difficulties in relating serum E2
concentrations to exposure to estrogen in target tissues,
particularly in postmenopausal women. It is also clear that
the hydroxylated estrogens are subsequently conjugated
locally by UGT enzymes, as suggested by previous
observations [9,41]. In the following section we address
the extensive knowledge on UGT enzymes and recent
findings that support a role for these enzymes in estrogen
inactivation in the breast tissue.
The glucuronidation process leads to
biologically inactive estrogens
Conjugation by glucuronidation, which is catalyzed by
UGT enzymes, is a pathway found in all vertebrates and
has primarily been studied because of its role in the
detoxification of exogenous compounds, mostly drugs
[48–51]. UGTs are membrane-bound enzymes that are249
present in the endoplasmic reticulum, which mediate
transfer of the ubiquitous co-substrate glucuronic acid
group of uridine diphospho-glucuronic acid to the
functional group (e.g. hydroxyl, carboxyl, amino, sulfur) of a
specific substrate. This biochemical reaction increases the
polarity of the target compound, and the resulting
glucuronide product is generally water soluble, less toxic,
and more easily excreted from the body than is the parent
compound. The glucuronide is subsequently recognized
by the biliary and renal organic anion transport systems,
which enable secretion into urine and bile. Because
addition of glucuronic acid to compounds changes their
structure, glucuronidation modifies the biological activity
of the parent molecule and therefore prevents it binding to
receptors. As a result, it is believed that most
glucuronides, including estrogen glucuronides, correspond
to inactive end-products of the parent estrogen and are
devoid of biologic activity.
Human UDP-glucuronosyltransferase
enzymes
Based on homology of primary structures, the UGT
proteins have been categorized into two families, UGT1
and UGT2, in which the latter is further subdivided into
two subfamilies, UGT2A and UGT2B. In humans, there
are 16 functional UGT proteins, of which nine are of the
UGT1 family (UGT1A1, A3–A10) and seven are of the
UGT2 family (UGT2B4, B7, B10, B11, B15, B17 and
B28) [48–50,52].
In contrast to the UGT2B subfamily, which comprises
several independent genes that are located on
chromosome 4q13 [53–55], members of the UGT1 family
are derived from a single gene locus (UGT1) that spans
about 210 kilobases on chromosome 2 (2q37) and is
composed of 17 exons [52,56,57]. To synthesize the final
protein, only one of 13 different exon-1 sequences on the
locus is associated with four downstream exons, which
are common to all UGT1 isoforms. Of the 13 exon-1
sequences, nine encode functional proteins (UGT1A1,
UGT1A3–1A10) and four correspond to pseudogenes (p;
UGT1A2p, UGT1A11p, UGT1A12p and UGT1A13p)
[52,56,57]. The regulatory sequences flanking each of the
exon 1 regions are thought to dictate the individual
expression profile of the UGT1 isoforms [52,58].
Two members of the UGT2A subfamily localized to
chromosome 4q13 have also been characterized and
share approximately 70% identity with the UGT2Bs. The
biologic function of UGT2As was proposed to be the
termination of odorant signals, although it is not limited to
this function because their transcripts have been detected
in the liver and several extrahepatic tissues [49,59,60].
UGT1 and UGT2 proteins are composed of 527–530
amino acid residues, for a molecular weight of 50–57 kDa.
The exon-1 sequence of UGTs encodes the substrate-
binding domain (amino-terminal half of the protein),
whereas the four common exons of the UGT1 gene and
exons 2–6 of the UGT2B genes encode the co-substrate-
binding domain (carboxyl-terminal half of the protein). The
presence of different possible substrate-binding domains
confers the great substrate specificity and selectivity of
UGT proteins, together with their broad tissue expression
profiles. UGTs are localized in the liver and in all ports of
entry of chemicals, including the epithelial surfaces of the
nasal mucosa, the gut, skin, white blood cells and lung
[58], and they probably play a pivotal role in eliminating
synthetic substances and pollutants.
Although it was believed for many years that glucuro-
nidation is a process limited to elimination of exogenous
compounds and synthetic drugs, recent data indicate that
these enzymes represent key elements in the homeostasis
of a number of endobiotics, including steroid and thyroid
hormones, bilirubin, fatty acids, and biliary acids
[10,61–64]. For instance, in a steroid target tissue such
as the prostate, high concentrations of glucuronides from
dihydrotestosterone metabolites have been measured,
and expression of highly specific androgen-conjugating
UGT enzymes UGT2B15 and UGT2B17 has been
detected [65]. It is believed that these polar metabolites
represent the final step of androgen metabolism in this
tissue.
Glucuronidation of estrogens by
UDP-glucuronosyltransferases expressed in
the breast tissue
Knowledge on the substrate specificity of human UGT
enzymes for estrogens has progressed significantly in
recent years. Data indicate that members of the UGT1
family have preferential recognition for estrogens, whereas
only one member of the UGT2B subfamily, namely
UGT2B7, has been found to be active on these molecules
[66–71]. The bilirubin-conjugating enzyme UGT1A1 was
initially reported to possess very high specificity for E2 and
to be responsible for formation of E2-3-glucuronide (E2-3G)
in human liver [71,72]. Until recently little information was
available regarding the conjugation of catecholestrogens
and their methoxylated metabolites.
Glucuronidation of catecholestrogens may occur at three
sites of hydroxylation, namely 3, 17, and 2 or 4 (Fig. 2),
and localization of the glucuronide group on the steroid
molecule was only possible using high performance liquid
chromatography mass spectrometry comparison with
authentic standards [66]. Six UGTs – 1A1, 1A3, 1A8,
1A9, 1A10, and 2B7 – were found to conjugate E2 and
E1, their hydroxyls and their methoxy derivatives. The
regioselectivity of the glucuronidation reaction has been
demonstrated for E2, which is conjugated at positions 3
and 17 by at least two different UGTs, namely UGT1A1
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and UGT2B7, respectively [67,73,74]. In the case of
catecholestrogens, glucuronidation occurs predominantly
at the 3-hydroxyl position of 2-OHCEs and the 4-hydroxyl
position of 4-OHCEs and is performed by a limited
number of UGT enzymes (Fig. 2) [66]. These reactions are
mostly mediated by UGT1A1 and UGT1A8, which have a
preference for 2-hydroxy E1 and 2-hydroxy E2, whereas
UGT2B7 has greater specificity for 4-hydroxy E1 and 4-
hydroxy E2 (Fig. 2) [13,68,75,76].
These data were obtained using UGT proteins that are
over-expressed in eukaryotic cells, but little is known
regarding the actual level of their formation in breast
tissue. On the other hand, the presence of high levels of
estrogen glucuronides in breast cyst fluid strongly
suggests that estrogen glucuronides are formed in situ.
This observation was recently confirmed in studies that
demonstrated expression of several UGTs in estrogen-
sensitive tissues, including breast tissue [13,14,16,66,
77]. In addition, the capacity of breast tissue to form
estrogen glucuronides in vitro was demonstrated by
enzymatic assays [13]. Accordingly, given the substrate
specificity of UGTs for E2 and its various metabolites, and
their presence in the breast, it is believed that this
pathway may contribute to in situ metabolic transformation
of estrogen and participate in the maintenance of their
homeostasis [13–16,78].
Recent data on the potential role played by
UDP-glucuronosyltransferases in breast
cancer risk
UGT enzymes that metabolize estrogen to inactive
compounds are highly polymorphic in humans (for review
[50]). The presence of genetic variations associated with
altered enzymatic activity or expression of this metabolic
pathway may result in significant changes in breast
estrogen levels and subsequent modification of cancer
risk. To date, few investigations have tested this hypo-
thesis. Studies of the associations between genetic poly-
morphisms, hormone circulating levels, and breast cancer
risk may yield important insights into the physiologic roles
played by these enzymes.
Four population-based studies of breast cancer patients
have assessed the association between genetic variability
in the E2 conjugating UGT1A1 enzyme and risk for breast
cancer [14,15,17,19]. UGT1A1 is expressed in human
breast parenchyma and is involved in the formation of the
major glucuronide of E2, E2-3G [14,73]. UGT1A1 status is
genetically determined by the presence of a common
polymorphism in its promoter region. This polymorphism is
characterized by a variation in the number of TA repeats in
the TATA box region of the gene. Six TA repeats
characterizes the common allele (UGT1A1*1) whereas the
most common variant allele consists of seven TA repeats
in the A(TA)nTAA motif (UGT1A1*28). Two less frequent
alleles, A(TA)5TAA and A(TA)8TAA, are referred to as
UGT1A1*36 and UGT1A1*37 [79]. In in vitro
investigations it has been demonstrated that the presence
of seven and eight repeats leads to a decrease in UGT1A1
gene expression [14,80,81]. Based on these findings, the
four  UGT1A1 promoter alleles were divided into two
phenotypic classes [15,80–83]. The first category of
alleles are alleles with high transcriptional activity
(UGT1A1*1 and *36), and their presence results in high
levels of UGT1A1 protein. The second group of alleles –
the low transcriptional activity alleles (UGT1A1*28 and
*37) – lead to lower levels of expressed UGT1A1 protein.
In epidemiologic studies it was hypothesized that the
presence of lower levels of UGT1A1 protein (individuals
with UGT1A1*28 and *37) would result in decreased
production of estrogen glucuronides and consequently
potential higher exposure to E2 as compared with patients
who carry the UGT1A1*1 and/or *36 alleles. This
hypothesis was first tested in an analysis of 200 African-
American women with invasive breast cancer and 200
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Figure 2
Regioselectivity of human UDP-glucuronosyltransferases (UGTs) for
parent estrogens estrone (E1) and estradiol (E2), their catechol
estrogens metabolites 2-hydroxy (OH)E1/E2 and 4-OHE1/E2, and their
methoxy metabolites 2-methoxy (MeO)E1/E2 and 4-MeOE1/E2. Red is
used for E2 and its metabolites, whereas blue refers to E1 and its
metabolites.251
matched control individuals [14], which revealed that the
low activity alleles (UGT1A1*28 [A(TA)7TAA] and
UGT1A1*37 [A(TA)8TAA]) were slightly positively
associated with breast cancer (odds ratio [OR] 1.8, 95%
confidence interval [CI] 1.0–3.1; P = 0.06). Among
premenopausal women the association was stronger for
estrogen receptor (ER)-negative breast cancer (OR 2.1,
95% CI 1.0–4.2; P = 0.04) than for ER-positive breast
cancer (OR 1.3, 95% CI 0.6–3.0; P = 0.5). A second
study [19] suggested that the risk for ER-negative tumors
is increased in the presence of polymorphism in the
UGT1A1 gene. This second, recent study was conducted
in 163 (mostly postmenopausal) women, diagnosed with
stage I breast cancer and enrolled in the HEAL (Health,
Eating, Activity and Lifestyle) study [19]. Contrary to the
reported association of UGT1A1  genotype with an
elevated risk for breast cancer in premenopausal African-
American women, this second study found a reduced risk
for ER-negative breast tumor (OR 0.0, 95% CI 0.0–0.5; P
for trend = 0.03) in breast cancer women with the
UGT1A1  variant *28/*28 genotype as compared with
UGT1A1*1/*1.
The mechanism by which estrogen leads to the develop-
ment of ER-negative tumors is not well understood, but it
is clear that hormones are essential to the genesis of both
hormone dependent and independent mammary tumors
[84–86]. Hormones can trigger the development of ER-
negative tumors via hormone-induced stimulation and
secretion of growth factors produced by hormone
responsive ER-positive cells or other mammary cell types.
Furthermore, ER-negative tumors may arise following
prolonged exposure and inadequate elimination of
catecholestrogen reactive metabolites formed locally in
the mammary gland.
The relationship between UGT1A1 variant alleles and risk
for breast cancer was not observed in a larger study of
455 Caucasian women with breast cancer and 603
women without breast cancer within the Nurses’ Health
Study [15]. A fourth study investigated 1047 breast
cancer cases and 1083 community-based control
individuals as part of the Shanghai Breast Cancer Study
[17] – a population-based case–control study. Consistent
with the increased risk observed among premenopausal
African-American women [14], a higher risk for breast
cancer was evident only in those Chinese women who
were younger than 40 years (OR 1.7, 95% CI 1.0–2.7),
and not among women who were 40 years old or older
(OR 0.8, 95% CI 0.7–1.1) [17].
Analysis of the relationship of this UGT1A1 polymorphism
and levels of circulating estrogens revealed that healthy
postmenopausal women who were not using hormone
replacement therapy tended to have higher E2 and E1
levels associated with the low activity allele [15].
Consistent with these findings, Sparks and coworkers
[19] recently showed that breast cancer patients with the
UGT1A1*28 homozygous variant genotype tended to
have increased concentrations of E2 as compared with
cancer patients with the UGT1A1*1/*1 genotype.
However, in that study of breast cancer patients, the
majority of women were overweight and on tamoxifen
therapy, which may alter estrogen levels independent of
UGT1A1 genotype.
These findings support a role of the glucuronidation
pathway in estrogen metabolism and its potential
contribution to the regulation of the estrogenic
environment in target cells. Additional studies are needed
to assess clearly the relationship between UGT genotypes
and hormonal status in healthy women and women with
breast cancer. In support of the potential role of UGTs in
modulating exposure of breast cells to hormones, a recent
report suggested that inter-individual differences in
estrogen glucuronidation influence breast density.
Compared with women with the UGT1A1*1/*1 genotype,
premenopausal women with the UGT1A1*28 allele had a
lower breast density (–43.1% difference; P = 0.04)
whereas postmenopausal women presented with greater
breast density (+32.0% difference; P = 0.05) [78].
However, the effect of aging on the relationship between
UGT1A1 genotype and breast density remains unclear.
Based on the direction of the changes in breast density
observed among women with different UGT1A1
genotypes, we would expect premenopausal women with
the UGT1A1*28 allele to have decreased risk for breast
cancer, and postmenopausal women with the
UGT1A1*28 allele to have increased risk. However, as
stated above, the UGT1A1 genotype did not alter risk for
breast cancer in the large, nested, case–control study
from the Nurses’ Health Study [15], in which the
Caucasian women studied in relation to breast density
were a subset. It seems that the effect on breast density
may be insufficient to modify breast cancer risk via the
UGT1A1-mediated pathway.
These preliminary findings raise a number of questions. It
is not known whether this polymorphism in the UGT1A1
gene has a direct effect on altering estrogen glucuro-
nidation, and indeed whether it would affect solely E2
glucuronidation or the conjugation of its hydroxylated and
methoxylated metabolites, as predicted by the in vitro
metabolic profile for estrogens [66]. It is likely that
polymorphisms in other UGTs that are active toward
various estrogens may also play a role. In addition, inter-
individual differences in estrogen glucuronidation due to
other environmental and dietary factors may also influence
breast density or breast cancer risk. In fact, it is still largely
unknown how breast tissues metabolize via the glucuro-
nidation pathway under physiologic and pathologic
conditions. The available data concerning the difference in
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expression of UGT in normal versus cancer cells suggest
that this metabolic pathway is downregulated during
breast carcinogenesis, and as a consequence this would
allow greater exposure to estrogen. More specifically,
expression of UGT2B7, a 4-OHCE metabolizing UGT
[66,87], was shown to be decreased in cancerous
mammary gland tissue as compared with normal tissue,
and was over-expressed in in situ lesions [13].
Furthermore, the presence of the UGT2B7 protein was
shown to be highly variable between individuals in the
epithelium lining the mammary gland ductal system. A
previous study reported that glucuronidation activity was
lower in breast cancer specimens as compared with
normal tissues [88]. Because UGT2B7 is highly reactive
UGT for 4-OHCEs, it was suggested that UGT2B7 would
protect the mammary gland from genotoxic 4-OHCEs
(bearing in mind that mammary gland is a tissue that also
expresses CYP1B1, which is involved in the local
formation of 4-OHCE) [89,90]. In support of this
hypothesis, Gestl and coworkers [13] measured glucuro-
nidation rates of 4-hydroxy E1, and activities were
significantly lower in neoplastic tissues than in normal
tissues, which is consistent with the hypothesis of a locally
protective role of the UGT2B7 enzyme. To date, no
expression data are available for other UGTs in cancer
versus normal breast tissues, and it remains to be clearly
demonstrated whether alterations in glucuronidation rates
or expression levels result in increased estrogen
bioavailability within target cells and consequent impact
on cancer risk. Analytical methods for the analysis of
estrogen glucuronides would need to be developed to
address these issues carefully.
To conclude, recent findings support possible influences of
the  UGT1A1 genotype and UGT2B7  expression on
metabolism and excretion of estrogen, which might affect
the hormonal status of the breast and therefore modulate
the risk for developing cancer. However, conflicting
findings raised questions, particularly regarding the role
played by UGT1A1 genotypes. Overall, the findings have
revealed differences in associations of UGT1A1 genotypes
with ER-negative breast cancer and breast density by
menopausal status, and this needs additional corrobora-
tion. Racial differences in susceptibility to breast cancer
associated with genetic factors such as polymorphisms in
the UGT1A1 promoter were also evident. Larger studies
are needed to uncover its exact role as well as the
involvement of other estrogen-metabolizing UGTs.
Conclusion
Little is known on the biologic role of UGTs in estrogen
target cells, but recent data support a key inactivation role
of this biochemical pathway in breast tissue. This function
is distinctive of those of other phase I and II metabolizing
enzymes such as CYPs and COMT, which lead
respectively to the generation of reactive metabolites,
some with carcinogenic effects, and estrogen methoxy
metabolites that possess protective properties. It is now
clear that UGTs confer polarity to a wide range of
estrogens and that this reaction not only takes place in the
liver but also in estrogen target tissues, producing
glucuronides of estrogens that are readily excreted from
the tissues and released into the circulation. Nevertheless,
the UGT-mediated metabolic pathway remains a largely
unexplored area in the field of estrogen metabolism, but
recent data point toward the concept that this pathway
may participate in the homeostasis of tissue concen-
trations of E1, E2, catechol estrogens, and methoxy
derivatives, in coordination with P450-mediated hydroxy-
lations and COMT-mediated methylation.
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